Ruvan-Z

Rosuvastatin + Ezetimibe

Composition

Ruvan-Z 5/10 mg Tablet: Each film coated tablet contains Rosuvastatin Calcium BP equivalent to Rosuvastatin 5 mg & Ezetimibe USP 10 mg.
Ruvan-Z 10/10 mg Tablet: Each film coated tablet contains Rosuvastatin Calcium BP equivalent to Rosuvastatin 10 mg & Ezetimibe USP 10 mg.
Ruvan-Z 20/10 mg Tablet: Each film coated tablet contains Rosuvastatin Calcium BP equivalent to Rosuvastatin 20 mg & Ezetimibe USP 10 mg.

Pharmacology

Rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In in-vivo and in-vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Rosuvastatin also inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles. Ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood.

Indication

Ruvan-Z is indicated in adults:

- As an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).
- Alone or as an adjunct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.

Dosage And Administration

The dosage range is 5 mg/10 mg to 40 mg/10 mg once daily. The recommended dose of **Ruvan-Z** depends on a patient's indication for usage, LDL-C, and individual risk for cardiovascular events. The starting dosage for patients switching to **Ruvan-Z** from co-administration of a statin and ezetimibe is based on an equivalent dose of rosuvastatin and 10 mg of ezetimibe.

Dosage in Asian Patients: Initiate **Ruvan-Z** at 5 mg/10 mg daily due to increased rosuvastatin plasma concentrations. Consider the risk/benefit when treating Asian patients not adequately controlled at doses up to 20 mg/10 mg once daily.

Dosage in Patients with Renal Impairment: In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m^2) not on hemodialysis, the recommended starting dosage is 5 mg/10 mg once daily and should not exceed 10 mg/10 mg once daily. There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

Contraindication

Ruvan-Z is contraindicated in patients with:

- Acute liver failure or decompensated cirrhosis.
- Hypersensitivity to rosuvastatin, ezetimibe, or any excipients in rosuvastatin & ezetimibe. Hypersensitivity reactions including anaphylaxis, angioedema, and erythema multiforme have been reported.

Adverse Reactions

Most common adverse reactions for:

- Rosuvastatin (incidence >2% and greater than placebo) are headache, nausea, myalgia, arthralgia, dizziness, asthenia, constipation, and abdominal pain.
- Ezetimibe (incidence >2% and greater than placebo) are upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.
- Ezetimibe co-administered with a statin (incidence >2% and greater than statin alone) are nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue.

Warning & Precautions

Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher **Ruvan-Z** dosage. Discontinue **Ruvan-Z** if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue **Ruvan-Z** in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients about the risk of myopathy and rhabdomyolysis when starting or increasing **Ruvan-Z** dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use.
Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzyme tests before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue **Ruvan-Z**.

Drug Interaction

- Gemfibrozil or Cyclosporin: Avoid concomitant use with **Ruvan-Z**.
- Antivirals: Avoid concomitant use of **Ruvan-Z** with certain antivirals and adjust the dose with other antivirals.
- Darolutamide: Do not exceed 5 mg/10 mg once daily.
- Regorafenib: Do not exceed 10 mg/10 mg once daily.
- Fenofibrates, Niacin, Colchine: Consider the risks and benefits of concomitant use with the drug.

Use in Specific Populations

Use in Pregnancy: May cause fetal harm. **Lactation:** Breastfeeding not recommended during treatment with **Ruvan-Z**.
Pediatric Use: The safety and effectiveness of **Ruvan-Z** have not been established in pediatric patients.
Geriatric Use: Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy and the higher risk of myopathy.

Storage

Store at 30° C and dry place, protect from light & moisture. Keep out of the reach of children.

Packing

Ruvan-Z 5/10 Tablet: Each box contains 30's tablets in Alu-Alu blister pack.
Ruvan-Z 10/10 Tablet: Each box contains 30's tablets in Alu-Alu blister pack.
Ruvan-Z 20/10 Tablet: Each box contains 20's tablets in Alu-Alu blister pack.

Manufactured by:
ARISTOPHARMA LTD.
Shampur-Kadamtali I/A, Dhaka-Bangladesh